These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9057092)

  • 1. Mdm-2: "big brother" of p53.
    Momand J; Zambetti GP
    J Cell Biochem; 1997 Mar; 64(3):343-52. PubMed ID: 9057092
    [No Abstract]   [Full Text] [Related]  

  • 2. P53 and mdm-2: interactions between tumor suppressor gene and oncogene products.
    Perry ME; Levine AJ
    Mt Sinai J Med; 1994 Sep; 61(4):291-9. PubMed ID: 7969222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploiting the p53 pathway for cancer diagnosis and therapy.
    Lane DP
    Br J Cancer; 1999 Jul; 80 Suppl 1():1-5. PubMed ID: 10466753
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
    Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
    Sourvinos G; Spandidos DA
    Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 is a central node in the p53 pathway: 12 years and counting.
    Bond GL; Hu W; Levine AJ
    Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The regulation of p53-mediated transcription and the roles of hTAFII31 and mdm-2.
    Lu H; Lin J; Chen J; Levine AJ
    Harvey Lect; 1994-1995; 90():81-93. PubMed ID: 8803320
    [No Abstract]   [Full Text] [Related]  

  • 9. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.
    Freedman DA; Levine AJ
    Cancer Res; 1999 Jan; 59(1):1-7. PubMed ID: 9892174
    [No Abstract]   [Full Text] [Related]  

  • 12. Mdm2: keeping p53 under control.
    Piette J; Neel H; Maréchal V
    Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mdm2, p53 and the cell cycle: when well enough is best left alone].
    Maréchal V
    Pathol Biol (Paris); 1997 Dec; 45(10):824-32. PubMed ID: 9769946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic exploitation of the p53 pathway.
    Lane DP; Lain S
    Trends Mol Med; 2002; 8(4 Suppl):S38-42. PubMed ID: 11927286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.
    Zietz C; Rössle M; Haas C; Sendelhofert A; Hirschmann A; Stürzl M; Löhrs U
    Am J Pathol; 1998 Nov; 153(5):1425-33. PubMed ID: 9811333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutations and MDM-2 amplification in renal cell cancers.
    Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2.
    Blaydes JP; Gire V; Rowson JM; Wynford-Thomas D
    Oncogene; 1997 Apr; 14(15):1859-68. PubMed ID: 9150392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of MDM-2 gene amplification in experimentally induced tumors regardless of p53 status.
    Saez GT; Oliva MR; Mangues R; Pellicer A
    Mol Carcinog; 1994 Jan; 9(1):40-5. PubMed ID: 8297484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
    Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
    Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.
    Meng RD; Shih H; Prabhu NS; George DL; el-Deiry WS
    Clin Cancer Res; 1998 Jan; 4(1):251-9. PubMed ID: 9516979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.